Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Oxygen therapy -150% Improvement Relative Risk Hospitalization -150% Recovery 7% Case 1% c19colchicine.com Correa-Rodríguez et al. Colchicine Prophylaxis Favors colchicine Favors control
Correa-Rodríguez, 244 patient colchicine prophylaxis study: 150% higher need for oxygen therapy [p=1], 150% higher hospitalization [p=1], 7% improved recovery [p=1], and 1% fewer cases [p=1] https://c19p.org/correarodriguez
copied to clipboard
Clinical course of Covid-19 in a cohort of patients with Behçet disease
Correa-Rodríguez et al., Medicina Clínica (English Edition), doi:10.1016/j.medcle.2022.08.009
19 Sep 2022    Source   PDF   Share   Tweet
Retrospective 244 Behçet disease patients in Spain, showing no significant difference in outcomes with colchicine treatment. Confounding by indication may significantly affect results - colchicine may be prescribed more often for more serious cases, which may have a higher baseline risk for COVID-19.
risk of oxygen therapy, 149.7% higher, RR 2.50, p = 1.00, treatment 1 of 163 (0.6%), control 0 of 81 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of hospitalization, 149.7% higher, RR 2.50, p = 1.00, treatment 1 of 163 (0.6%), control 0 of 81 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of no recovery, 7.1% lower, RR 0.93, p = 1.00, treatment 13 of 24 (54.2%), control 7 of 12 (58.3%), NNT 24, full recovery at 6 months.
risk of case, 0.6% lower, RR 0.99, p = 1.00, treatment 24 of 163 (14.7%), control 12 of 81 (14.8%), NNT 1100.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Correa-Rodríguez et al., 19 Sep 2022, retrospective, Spain, peer-reviewed, mean age 44.0, 6 authors.
Contact: macoro@ugr.es.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit